Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Lenzilumab Demonstrates Clinical Benefit in Patients With Chronic Myelomonocytic Leukemia

A phase I study found that lenzilumab, an engineered human IgG1K monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), was associated with a clinical...
WIB_icon

Radiation Alone Improves Outcomes in Early-Stage NLPHL Without High-Risk Features

Radiotherapy alone was associated with excellent progression-free survival (PFS) and low rates of late toxicity in patients with stages IA to IIA nodular lymphocyte-predominant...
WIB_icon

Prophylaxis Does Not Fully Prevent VTE Risk in Patients With ALL Treated With Asparaginase

Antithrombin (AT) replacement and heparin prophylaxis was not entirely effective for the prevention of venous thromboembolism (VTE) in adult patients with acute lymphocytic leukemia...
WIB_icon

International Prognostic Score Predicts Time to First Treatment in Patients With Early-Stage CLL

An international prognostic score (IPS-E) consisting of a sum score for three markers for consistently predicted time to first treatment (TTFT) in patients with...
WIB_icon

Comparing Anticoagulant Effect of Edoxaban in Patients With Cirrhosis Against Healthy Controls

Edoxaban, an anti-factor Xa targeting direct oral anticoagulant (DOAC), is a less effective inhibitor of coagulation in patients with cirrhosis than in healthy individuals,...
WIB_icon

IWG-PM Publishes Proposed Diagnostic Criteria for SF3B1-Mutant MDS

The International Working Group for the Prognosis of MDS (IWG-PM) has published a proposal for new diagnostic criteria for SF3B1-mutant myelodysplastic syndromes (MDS) as...
WIB_icon

Predicting Survival in MM With Renal Impairment and Light Chain Cast Nephropathy

The quality of renal response to therapy was associated with survival in patients with multiple myeloma (MM) with renal impairment and light chain cast...
WIB_icon

BTKi Improves Disease Control in CLL After Progression on Venetoclax

Treatment with a Bruton tyrosine kinase inhibitor (BTKi) showed efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed on venetoclax, according to...
WIB_icon

Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?

Compared with the widely used International Prognostic Index (IPI) and revised IPI (R-IPI), the most recent National Comprehensive Cancer Network IPI (NCCN-IPI) better predicts...
WIB_icon

Ruxolitinib Improves Outcomes in Patients With Steroid-Refractory Graft-Versus-Host Disease

Patients with steroid-refractory acute graft-versus-host disease (GVHD) following hematopoietic cell transplant (HCT) experienced durable clinical responses by 28 days and had promising overall survival...
Advertisement

Current Issue

July 2020 Volume 6 Issue 8

This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.